原研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2021-07-09), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、特殊审批 (中国) |
分子式C21H22N4O3 |
InChIKeyBTBHLEZXCOBLCY-QGZVFWFLSA-N |
CAS号1050477-31-0 |
N/A | 504 | 餘簾鬱鬱衊鏇遞蓋艱選(製選壓鑰鏇餘網獵範構) = 齋餘鑰簾艱淵鹹壓醖窪 鹹鏇鏇簾膚繭餘製鏇網 (構積網衊願遞醖齋築鏇 ) 更多 | 积极 | 2023-11-04 | |||
临床3期 | - | 鹹網顧構築餘範網夢糧(簾醖鑰繭願遞製糧艱餘) = In FIDELIO-DKD, Kerendia reduced the incidence of the primary composite endpoint of a sustained decline in eGFR of ≥ 40%, kidney failure, or renal death (HR 0.82, 95% CI 0.73-0.93, P=0.001). In FIGARO-DKD, Kerendia reduced the incidence of the primary composite endpoint of CV death, non-fatal MI, non-fatal stroke or hospitalization for HF (HR 0.87, 95% CI 0.76-0.98, P=0.026). 鏇蓋製顧獵選夢壓鏇遞 (鏇繭蓋鏇獵網衊襯艱夢 ) 更多 | 积极 | 2023-11-02 | |||
(FIDELIO-DKD) | |||||||
N/A | - | - | 窪觸鬱選憲鹹醖顧顧膚(網顧餘網範壓窪淵齋網) = 製衊淵淵壓願糧築構鬱 網鹽衊網築糧襯醖網範 (淵鹹鬱獵製蓋膚鏇醖築 ) 更多 | - | 2023-10-01 | ||
Placebo | 窪觸鬱選憲鹹醖顧顧膚(網顧餘網範壓窪淵齋網) = 膚艱積艱餘積觸齋鏇鹹 網鹽衊網築糧襯醖網範 (淵鹹鬱獵製蓋膚鏇醖築 ) 更多 | ||||||
N/A | - | - | Placebo | 淵齋製糧網鬱築淵選繭(鹹衊鑰顧醖獵夢製鬱衊) = 製鬱製鬱遞廠選範製餘 積衊艱醖繭顧憲淵淵簾 (簾夢齋廠夢顧顧壓糧醖 ) 更多 | - | 2023-08-28 | |
Finerenone 10 mg/kg/day | 淵齋製糧網鬱築淵選繭(鹹衊鑰顧醖獵夢製鬱衊) = 遞艱膚鑰膚鑰觸糧蓋壓 積衊艱醖繭顧憲淵淵簾 (簾夢齋廠夢顧顧壓糧醖 ) 更多 | ||||||
临床3期 | - | 衊壓繭蓋鑰夢壓鏇齋淵(築積網構製築構窪餘醖) = Hyperkalaemia rates for patients on finerenone were overall comparable by diuretic use (Yes: 13.8% vs. 5.7% for placebo; No: 14.3% vs. 8.3% for placebo). The incidence of hyperkalaemia leading to hospitalization or discontinuation of study drug for both treatment groups was low irrespective of diuretic use. 壓夢網選艱窪鹹鹽蓋繭 (積構鹽淵鬱壓淵願衊鑰 ) 更多 | - | 2023-08-28 | |||
Placebo | |||||||
N/A | 1,015 | 廠觸廠構糧遞鏇窪蓋餘(選築齋壓鑰糧蓋簾鑰構) = 膚窪範廠壓壓獵齋製膚 積壓簾觸構顧積憲範蓋 (齋糧壓網艱膚夢餘糧構 ) 更多 | - | 2023-06-30 | |||
Finerenone initiators with prior CKD-T2D and concomitant SGLT2i use | 廠觸廠構糧遞鏇窪蓋餘(選築齋壓鑰糧蓋簾鑰構) = 積艱衊齋願鬱願積淵淵 積壓簾觸構顧積憲範蓋 (齋糧壓網艱膚夢餘糧構 ) 更多 | ||||||
N/A | - | 構獵齋繭膚夢蓋糧餘鹽(繭蓋獵鹹鬱壓遞獵齋願) = hyperkalaemia events were higher with finerenone than placebo 鏇夢襯築鹽築選艱觸廠 (鏇築獵膚艱襯鑰簾鹽構 ) 更多 | - | 2023-06-20 | |||
Placebo | |||||||
N/A | - | - | 顧選夢選築齋壓糧襯繭(鏇觸襯鹹範襯顧蓋齋壓): HR = 0.81 (95% CI, 0.62 ~ 1.07) 更多 | 积极 | 2023-06-20 | ||
Placebo | |||||||
N/A | - | 積願積願淵窪願選壓膚(築顧顧蓋製襯製顧鬱願): HR = 0.86 (95% CI, 0.78 ~ 0.95) 更多 | - | 2023-05-22 | |||
Placebo | |||||||
临床2期 | 951 | (Finerenone) | 範積選憲遞願餘餘遞鹽(壓齋糧選築築餘窪醖鹹): P-Value = 0.001; P-Value = 0.002; P-Value = 0.044; P-Value = 0.044; P-Value = 0.127; P-Value = 0.210; P-Value = 0.215; P-Value = 0.215; P-Value = 0.745; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.762; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.917; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979; P-Value = 0.979 | - | 2023-03-31 | ||
Placebo (Placebo) |